Gossypol Inhibits Metastasis of Lung Cell Carcinoma by Reversing Epithelial to Mesenchymal Transition and Suppressing...

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Gossypol, a natural polyphenolic compound, exhibits known antiviral and anti-tumor properties.
• The anti-metastatic and anti-epithelial-to-mesenchymal transition (EMT) effects of gossypol on lung carcinoma are not well understood.

Purpose of the Study:

• To investigate the cellular and molecular mechanisms underlying the anti-cancer and anti-metastatic effects of gossypol on human lung carcinoma cells.
• To evaluate gossypol's impact on cell viability, motility, invasion, and EMT.

Main Methods:

• Cell viability, motility, and invasion assays were performed on H1299 and A549 lung carcinoma cell lines.
• Zymography was used to assess urokinase-type plasminogen activator and matrix metalloproteinase-2 activity.
• Western blotting was employed to analyze protein expression changes, including vimentin, p-FAK, p-Src, and p-paxillin.
• In vivo studies involved subcutaneous inoculation and tail vein injection of A549 cells in immunodeficient mice.

Main Results:

• Gossypol significantly suppressed the viability, motility, and invasion of H1299 and A549 lung carcinoma cells.
• Gossypol inhibited the activities of urokinase-type plasminogen activator and matrix metalloproteinase-2.
• Gossypol effectively reversed transforming growth factor-beta (TGF-β)-induced epithelial to mesenchymal transition (EMT).
• Gossypol treatment led to reduced levels of vimentin, p-FAK, p-Src, and p-paxillin, key markers of EMT and cell signaling.

Conclusions:

• Gossypol demonstrates significant anti-cancer and anti-metastatic potential against human lung carcinoma.
• Gossypol exerts its effects by suppressing cell viability, motility, invasion, and reversing EMT.
• The findings suggest gossypol as a promising therapeutic candidate for lung cancer treatment.